BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38712609)

  • 21. PD-L1
    Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
    Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
    [No Abstract]   [Full Text] [Related]  

  • 22. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
    Zou L; Liu K; Shi Y; Li G; Li H; Zhao C
    Cancer Biomark; 2023; 36(4):299-311. PubMed ID: 36938729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
    Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
    Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection.
    Chen KJ; Zhou L; Xie HY; Ahmed TE; Feng XW; Zheng SS
    Med Oncol; 2012 Sep; 29(3):1817-26. PubMed ID: 21678026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
    Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
    Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells.
    Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB
    Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.
    Shen X; Li N; Li H; Zhang T; Wang F; Li Q
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1745-54. PubMed ID: 20221638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD74
    Xiao N; Li K; Zhu X; Xu B; Liu X; Lei M; Sun HC
    Cancer Immunol Immunother; 2022 Jan; 71(1):57-69. PubMed ID: 34009409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor-infiltrating FoxP3+ Tregs are associated with CD34 expression and prognosis of hepatocellular carcinoma].
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; DU Z
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):25-9. PubMed ID: 22464702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXP3 and SQSTM1/P62 correlate with prognosis and immune infiltration in hepatocellular carcinoma.
    Liu S; Zhang H; Yan J; Zhu J; Bai Z; Li X
    Pathol Res Pract; 2023 Feb; 242():154292. PubMed ID: 36630868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Specific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patients].
    Zhang HH; Fei R; Xie XW; Wang L; Luo H; Wang XY; Wei L; Chen HS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 41(3):313-8. PubMed ID: 19727215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment.
    Dituri F; Mancarella S; Serino G; Chaoul N; Lupo LG; Villa E; Fabregat I; Giannelli G
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human hepatocellular carcinoma-infiltrating CD4⁺CD69⁺Foxp3⁻ regulatory T cell suppresses T cell response via membrane-bound TGF-β1.
    Han Y; Yang Y; Chen Z; Jiang Z; Gu Y; Liu Y; Xu S; Lin C; Pan Z; Zhou W; Cao X
    J Mol Med (Berl); 2014 May; 92(5):539-50. PubMed ID: 24668348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4
    Lo Re O; Mazza T; Giallongo S; Sanna P; Rappa F; Vinh Luong T; Li Volti G; Drovakova A; Roskams T; Van Haele M; Tsochatzis E; Vinciguerra M
    Theranostics; 2020; 10(2):910-924. PubMed ID: 31903159
    [No Abstract]   [Full Text] [Related]  

  • 37. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
    J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma.
    Li ZQ; Wang HY; Zeng QL; Yan JY; Hu YS; Li H; Yu ZJ
    Cancer Med; 2020 Jan; 9(2):711-723. PubMed ID: 31769216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis.
    Lu LC; Deantonio C; Palu CC; Lee YH; Mitchell LS; Cowan M; Corser M; Sherry L; Cheng AL; Quaratino S; Shao YY; Sainson RCA; Hsu CH
    Oncology; 2022; 100(8):419-428. PubMed ID: 35709702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.